TNFRSF9 and neoplasm: Dual targeting of CD137 and HER aims to bridge CD137-expressing T-cells in close proximity to HER2-positive cancer cells, generating a strong signal to tumour antigen-specific T-cells, eliciting anti-tumour activity and thereby providing a potent costimulatory signal to tumour antigen-specific T-cells [88].